Preparation and preclinical evaluation of ^99mTc Glibenclamide formulation for detection of pancreatic problems

Diabetes mellitus is result of an absolute or relative reduction in pancreatic beta cell mass leading to insufficient secretion and hypoglycemia. Glibenclamide (GBD) is one of the most potent sulfonylurea derivatives used in the treatment of maturity-onset diabetes by inducing insulin secretion in pancreatic β cells. The present work was aimed to assess the pancreatic beta cell in normal healthy rat (animal) using SPECT-CT imaging. 10 mCi (± 1.0) ^99mTc were added to the drug solution and heat the vial in boiling water bath. Biodistribution studies were carried out of optimized product injected (5 MBq) into the teil vein of the healthy normal Wistar rat and SPECT-CT imaging was done at 45 min 6 hr and 18 hr post injection. The in vivo study of normal animal confirms the stability and shows that the drug is deposited very specifically at the pancreas. The ^99mTc-GBD is promising RP for imaging the pancreatic islet cell mass and to detect the problems in the initial stage of the disease noninvasively. for imaging of the pancreas is under progress. Standardization of dose in pancreatic tumor animal model evaluation will confirm the utility of the labeled product